Arcutis Biotherapeutics Balance Sheet
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcutis Biotherapeutics financial position
At the end of fiscal 2025, Arcutis Biotherapeutics reported total assets of $433.0 million, up 24.1% from a year earlier against total liabilities of $243.5 million. Shareholders' equity stood at $189.5 million, or 43.8% of assets. The company held $42.9 million in cash and equivalents against $109.0 million of debt, a net debt position of $66.1 million.
The current ratio (current assets divided by current liabilities) was 3.17, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.58.
Summary generated from market data by MetaCap's automated system. Methodology
Arcutis Biotherapeutics balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 42.91M | 71.33M | 88.39M | 53.64M | 96.45M | 65.08M | 63.34M | 39.39M |
| Short-Term Investments | 178.07M | 156.62M | 183.46M | 355.95M | 290.61M | 219.36M | 37.93M | — |
| Receivables | 146.23M | 73.07M | 25.81M | 8.46M | 0 | — | — | — |
| Inventory | 22.63M | 14.53M | 13.13M | 7.51M | 0 | — | — | — |
| Total Current Assets | 411.23M | 335.82M | 330.43M | 437.41M | 402.77M | 292.83M | 106.47M | — |
| Property, Plant & Equipment | 1.04M | 1.04M | 1.54M | 1.88M | 2.26M | 2.02M | 227.00K | — |
| Intangible Assets | 14.81M | 9.48M | 6.44M | 7.19M | 0 | — | — | — |
| Total Assets | 432.97M | 348.89M | 341.37M | 449.27M | 408.15M | 298.27M | 107.01M | — |
| Accounts Payable | 12.53M | 14.22M | 11.99M | 8.83M | 7.35M | 7.14M | 1.41M | — |
| Short-Term Debt | 1.00M | 0 | 0 | — | — | — | — | — |
| Total Current Liabilities | 129.84M | 81.01M | 46.67M | 37.81M | 33.33M | 22.60M | 5.24M | — |
| Long-Term Debt | 107.96M | 107.20M | 201.80M | 197.77M | 72.35M | 0 | — | — |
| Total Liabilities | 243.49M | 191.35M | 252.70M | 239.69M | 110.47M | 27.65M | 5.55M | — |
| Shareholders' Equity | 189.48M | 157.54M | 88.67M | 209.58M | 297.68M | 270.62M | -65.03M | -23.99M |
| Retained Earnings | -1.14B | -1.12B | -981.90M | -719.76M | -408.31M | -201.95M | -66.27M | — |
| Total Debt | 108.96M | 107.20M | 201.80M | 197.77M | 72.35M | 0 | — | — |
| Net Cash (Debt) | 112.02M | 120.75M | 70.06M | 211.82M | 314.71M | 284.44M | 101.27M | 39.39M |
| Shares Outstanding | 123.33M | 117.85M | 96.79M | 61.04M | 50.26M | 43.34M | 2.12M | — |
This table shows 8 annual periods of Arcutis Biotherapeutics's balance sheet, from FY 2025 back to FY 2018, across 18 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow ARQT's reporting calendar. What is a balance sheet?